Atopic Dermatitis Market
Atopic Dermatitis Market By Drug Class (Corticosteroids, PDE4 Inhibitors, Biologics, Skin Barrier Emollients, CNI Immunosuppressants), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), By Region - Global Market Insights 2019 to 2029
Development of Novel Drugs to Accelerate Market Growth
Dermatological disorders are highly prevalent in various forms across the globe. According to the World Health Organization, more than 900 million people were affected by skin diseases in 2017. Out of these diseases, atopic dermatitis affects more than 300 million people globally.
Around one-fifth of the victims include children. This increased incidence of this disease is expected to leverage the growth of the atopic dermatitis market in the foreseeable future.
Other factors, such as the development of novel pipeline drugs and rising demand for new biologics and product approvals, are also expected to augment atopic dermatitis drugs demand.
The global atopic dermatitis market is project to show a stellar CAGR of 24.1% between 2020 and 2027, surpassing a valuation of US$ 19 Bn by the end of the forecast period.
Avail customized purchase options for your needs
Biologics Drugs and PDE4 Inhibitors Account for Major Chunk of Market Share
The biologics drug segment maintained its supremacy in the global atopic dermatitis market in 2018. The segment will continue to acquire greater market share during the forecast period.
This is attributed to new product launches and increased adoption of biological drugs across several regions.
Projections indicate that the biologics segment is poised to account for a staggering CAGR of 32.1% between 2020 and 2027, surpassing a valuation of US$ 15 Bn.
This is followed by the growth of PDE4 Inhibitors, forecast to grow at a similar CAGR during the forecast period.
Increased affordability of treatment, extensive research and development of PDE4 Inhibitors and high adoption in key markets are factors driving growth.
Retail Pharmacies to be Lucrative Revenue Pockets of Global Atopic Dermatitis Market
By end-use, retail pharmacies are expected to be the most lucrative. Anticipated market share is pegged at almost four-fifth of the global atopic dermatitis market.
The growth of this segment is driven by increased number of retail pharmacy stores around the world and availability of small molecule drugs.
Easy availability of therapeutic drugs at the desired location, affordability and convenience are some other factors boosting the growth of the market. Projected CAGR for retail pharmacies amounts for 27% during the forecast period.
North America to Enjoy Burgeoning Growth, Europe Closing In
North America is anticipated to maintain its regional supremacy throughout the forecast period.
This is attributed to adoption of advanced products, adequate reimbursement coverage for pharmaceutical companies and greater market penetration of new players.
The region is anticipated to grow at a dexterous CAGR of 27% during the forecast period, comprising more than half the total share of the atopic dermatitis market.
Trailing behind North America is Europe, comprising around one-third of the global atopic dermatitis market.
Increased awareness about atopic dermatitis, favorable medical reimbursement policies and well-established healthcare facilities are projected to leverage Europe’s market share.
Expected CAGR is pegged at a robust 25% for the forecast period.
An Adaptive Approach to Modern-day Research Needs
Product Development to Remain Growth Lever for Market Players
The global atopic dermatitis drugs market is dominated by six key players. These are
- Mylan M.V.
- Pfizer Inc.
- LEO Pharma A/S
- Teva Pharmaceutical Industries Ltd
- Novartis AG.
Investment in research and development of new pharmaceutical drugs is the key strategy for market expansion of the aforementioned companies.
For example, Sanofi Genzyme manufactures the Biologics drug DUPIXNET ® which cures skin lesions and reduces itching.
It does so by inhibiting the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. These proteins are key contributors of type-2 inflammation which occurs in atopic dermatitis.
On a similar plane, Pfizer Inc., manufactures Eucrisa (crisaborole) which consists of PDE4 Inhibitors to treat skin ailments, particularly Eczema.
The ointment targets the enzyme Phosphodiesterase-4, or PDE4, by blocking the over reactive enzymes within skin cells to prevent inflammation.
Interested to Procure The Data
Global Atopic Dermatitis Drugs Market Segmentation
Fact.MR has studied the global atopic dermatitis drugs market with detailed segmentation on the basis product type, application and key regions.
By Drug Class :
- PDE4 Inhibitors
- Skin Barrier Emollients
- CNI Immunosuppressants
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Key Regions :
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
“This taxonomy prepared is confidential and intended exclusively for the individual or entity with whom it is being shared.
Reading, disseminating, distributing, or copying this to any party other than addressee(s) is unauthorized and prohibited.”